SCIENCE OF
POSSIBILITY
At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.
Vertex receives European Commission approval for its fourth medicine, for eligible children with cystic fibrosis aged 2 to 5 years old
Our CRISPR/Cas9 gene-edited treatment for sickle cell disease and transfusion-dependent beta thalassemia is approved by the UK MHRA
Vertex announces Q3 2023 financial results
Vertex to share new data on investigational therapy for the treatment of sickle cell disease and beta thalassemia at the 2023 American Society of Hematology (ASH) Annual Meeting
We are presenting data on our fourth approved medicine for the treatment of cystic fibrosis at the 2023 North American Cystic Fibrosis Conference
Working at Vertex
Working at Vertex
Our company is built on an inclusive culture that brings together the best and brightest in every field striving for one goal: to improve the lives of people with serious diseases.
Find a Vertex clinical trial
Volunteers who participate in clinical trials
help make new medicines a reality.
Featured Stories
Join us as we celebrate 15 years of giving back at Vertex.
Individuals living with severe sickle cell disease report higher exposure to health care prejudice, according to new research by our Health Economics and Outcomes Research (HEOR) team.
Chief Human Resources Officer Stephanie Franklin discusses Vertex’s inclusive benefits and how they are helping Vertexians.
Join us as we celebrate 15 years of giving back at Vertex.
Individuals living with severe sickle cell disease report higher exposure to health care prejudice, according to new research by our Health Economics and Outcomes Research (HEOR) team.
Chief Human Resources Officer Stephanie Franklin discusses Vertex’s inclusive benefits and how they are helping Vertexians.
